Center for Reproductive Sciences, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco (UCSF), United States.
Division of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, UCSF, United States.
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Apr 15;1169:122467. doi: 10.1016/j.jchromb.2020.122467. Epub 2020 Dec 10.
New all-oral regimens for rifampin-resistant tuberculosis (RR-TB) are being scaled up globally. Measurement of drug concentrations in hair assesses long-term drug exposure. Delamanid (DLM) is likely to be a key component of future RR-TB treatment regimens, but a method to describe its quantification in hair via liquid chromatography-tandem mass spectrometry (LC-MS/MS) has not previously been described. We developed and validated a simple, fast, sensitive, and accurate LC-MS/MS method for quantifying DLM and its metabolite DM-6705 in small hair samples. We pulverized and extracted two milligrams of hair in methanol at 37 °C for two hours, and diluted 1:1 with water. A gradient elution method eluted DLM, DM-6705, and the internal standard OPC 14714 within 3 min, bringing overall analysis time to 5.5 min. The method has limits of detection (LOD) of 0.0003 ng/mg for DLM and 0.003 ng/mg for DM-6705. The established linear dynamic ranges are 0.003-2.1 ng/mg and 0.03-21 ng/mg for DLM and DM-6705, respectively. Eleven of 12 participant hair samples had concentrations within DLM's linear dynamic range, while all 12 samples had concentrations within the quantifiable range for DM-6705. The ranges of concentrations observed in these clinical samples for DLM and DM-6705 were 0.004-0.264 ng/mg hair and 0.412-12.041 ng/mg hair respectively. We demonstrate that while DLM was detected in hair at very low levels, its primary metabolite DM-6705 had levels approximately 100 times higher. Measuring DM-6705 in hair may accurately reflect long-term adherence to DLM-containing regimens for drug-resistant TB.
用于耐利福平结核病(RR-TB)的新型全口服治疗方案正在全球范围内扩大规模。毛发中的药物浓度测量可评估长期药物暴露情况。德拉马尼(DLM)可能是未来 RR-TB 治疗方案的关键组成部分,但以前尚未描述通过液相色谱-串联质谱法(LC-MS/MS)描述其在毛发中定量的方法。我们开发并验证了一种简单、快速、灵敏和准确的 LC-MS/MS 方法,用于从小样本毛发中定量 DLM 及其代谢物 DM-6705。我们将 2 毫克毛发在 37°C 的甲醇中粉碎并提取 2 小时,然后用 1:1 的水稀释。梯度洗脱法在 3 分钟内洗脱 DLM、DM-6705 和内标物 OPC 14714,使总分析时间达到 5.5 分钟。该方法对 DLM 的检测限(LOD)为 0.0003ng/mg,对 DM-6705 的检测限为 0.003ng/mg。所建立的线性动态范围分别为 0.003-2.1ng/mg 和 0.03-21ng/mg 用于 DLM 和 DM-6705。12 名参与者毛发样本中有 11 份的浓度在 DLM 的线性动态范围内,而所有 12 份样本的浓度均在 DM-6705 的可定量范围内。在这些临床样本中观察到的 DLM 和 DM-6705 的浓度范围分别为 0.004-0.264ng/mg 毛发和 0.412-12.041ng/mg 毛发。我们证明,虽然 DLM 在毛发中以非常低的水平检测到,但它的主要代谢物 DM-6705 的水平约高 100 倍。在毛发中测量 DM-6705 可能准确反映出对含有 DLM 的耐药性结核病治疗方案的长期坚持。